Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to $9.0 million.

  • Coherus Oncology's Net Income towards Common Stockholders fell 7561.33% to $9.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $540.3 million, marking a year-over-year increase of 21772.8%. This contributed to the annual value of $28.5 million for FY2024, which is 11198.32% up from last year.
  • Coherus Oncology's Net Income towards Common Stockholders amounted to $9.0 million in Q3 2025, which was down 7561.33% from $342.6 million recorded in Q2 2025.
  • Coherus Oncology's Net Income towards Common Stockholders' 5-year high stood at $342.6 million during Q2 2025, with a 5-year trough of -$172.9 million in Q1 2021.
  • Moreover, its 5-year median value for Net Income towards Common Stockholders was -$39.6 million (2023), whereas its average is -$1.4 million.
  • In the last 5 years, Coherus Oncology's Net Income towards Common Stockholders tumbled by 58618.86% in 2021 and then soared by 71714.52% in 2025.
  • Quarter analysis of 5 years shows Coherus Oncology's Net Income towards Common Stockholders stood at -$45.7 million in 2021, then decreased by 28.75% to -$58.9 million in 2022, then plummeted by 35.3% to -$79.7 million in 2023, then soared by 348.34% to $197.8 million in 2024, then tumbled by 95.46% to $9.0 million in 2025.
  • Its Net Income towards Common Stockholders was $9.0 million in Q3 2025, compared to $342.6 million in Q2 2025 and -$9.2 million in Q1 2025.